OPKO Health, Inc. (NASDAQ:OPK) Receives Average Rating of “Hold” from Analysts

Shares of OPKO Health, Inc. (NASDAQ:OPK) have received an average recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $2.0333.

A number of equities analysts have issued reports on the company. Barrington Research reduced their target price on OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. JPMorgan Chase & Co. started coverage on shares of OPKO Health in a report on Thursday, November 20th. They set a “neutral” rating for the company. Finally, Wall Street Zen downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th.

Institutional Trading of OPKO Health

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in OPKO Health by 23.7% during the 2nd quarter. Geode Capital Management LLC now owns 10,424,473 shares of the biotechnology company’s stock worth $13,763,000 after buying an additional 1,995,633 shares during the period. Tejara Capital Ltd grew its stake in OPKO Health by 10.0% in the second quarter. Tejara Capital Ltd now owns 946,090 shares of the biotechnology company’s stock valued at $1,249,000 after acquiring an additional 85,746 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of OPKO Health by 94.5% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 391,664 shares of the biotechnology company’s stock worth $517,000 after acquiring an additional 190,319 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of OPKO Health by 115.3% in the third quarter. New York State Common Retirement Fund now owns 130,901 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 70,100 shares in the last quarter. Finally, Arizona State Retirement System raised its position in shares of OPKO Health by 45.8% during the third quarter. Arizona State Retirement System now owns 128,608 shares of the biotechnology company’s stock worth $199,000 after purchasing an additional 40,414 shares during the period. Institutional investors own 64.63% of the company’s stock.

OPKO Health Stock Performance

OPK stock opened at $1.19 on Tuesday. OPKO Health has a twelve month low of $1.11 and a twelve month high of $1.87. The company has a quick ratio of 3.52, a current ratio of 3.97 and a debt-to-equity ratio of 0.26. The company has a market cap of $903.29 million, a P/E ratio of -3.97 and a beta of 1.50. The business’s fifty day moving average is $1.25 and its 200-day moving average is $1.34.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The business had revenue of $148.50 million during the quarter, compared to analysts’ expectations of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The firm’s quarterly revenue was down 19.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.01 earnings per share. Equities research analysts forecast that OPKO Health will post -0.25 EPS for the current year.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.